Sandoz, a Novartis division, is a pioneer and a global leader in biosimilars. We invest in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics.
Sandoz was the first pharmaceutical company to receive approval of a biosimilar in Europe, Japan and the United States1-3.
Our biosimilars have been used in clinical practice for over 10 years, are available in almost 1004 countries and have over 530 million patient-days of experience5.
In addition to our eight marketed biosimilars across immunology, oncology and endocrinology, we also have a leading biosimilars pipeline with more than 10 molecules in various stages of development.
Sandoz has over 20 years of experience in biosimilar development1. This has equipped us with extensive knowledge and world-class expertise in the development, manufacture and delivery of biosimilar medicines to the healthcare community and patients.
We have a unique heritage in pharmaceutical biotechnology that dates back to the 1940s, with the development of penicillin5. In 1980, Sandoz produced one of the first recombinant proteins, an interferon alfa6.
After initiating the world’s first biosimilar development program in 1996, we went on to receive the world’s first approval of a biosimilar – Omnitrope® (somatropin) – in Europe over a decade ago1. Then, in 2015, Zarxio® (filgrastim) was the first biosimilar to be granted marketing authorization in the US3.
We have an unparalleled heritage in advancing biologic care – longer than any other company.